Key Highlights

● New student starts reached 6,342, up 10.9%, in the quarter ended June 30, 2026.

● Quarterly Revenue was $218.9 million, up 7.2%, while Net Income fell to $2.3 million.

● Fiscal 2026 revenue guidance now stands at $893 million to $900 million.

● UTI-Atlanta opened in July 2026 with initial starts about 30% ahead of expectations.

Universal Technical Institute Inc (NYSE:UTI) is approaching the end of its fiscal year with enrollment momentum and a lowered Earnings outlook sitting side by side. In its fiscal third-quarter report on August 5, 2026, the skilled-trades educator posted a double-digit rise in new student starts while cutting its full-year revenue, profit and Cash Flow guidance. Management attributed the change largely to timing and mix rather than weaker demand. With the fiscal year-end approaching, investors may be watching how the Concorde Acquisition and new campuses feed into results.

Latest Company Context

UTI operates 35 campuses nationwide and online, founded in 1965, and reports two segments: the UTI division and Concorde Career Colleges. Concorde was acquired on December 1, 2022, extending the company into healthcare education, and MIAT Houston, bought in November 2021, is being consolidated into the UTI Houston operation. For the quarter ended June 30, 2026, revenue was $218.9 million, up 7.2%, while net income fell to $2.3 million from $10.7 million. Adjusted EBITDA was $18.2 million, down 27.8%, and included $9.0 million of strategic growth investments. New student starts reached 6,342, up 10.9%, with the UTI division up 23.4% and Concorde down 1.4%. A first phase of a multi-phase restructuring plan was implemented in May 2026, with further phases planned over three years, according to the company.

Key Business and index Drivers

Updated fiscal 2026 guidance, which is management's outlook rather than a certainty, now calls for revenue of $893 million to $900 million, down from $905 million to $915 million. Net income is guided to $32 million to $36 million, Diluted Earnings per Share to $0.57 to $0.64, and adjusted EBITDA to $100 million to $103 million. New student starts are expected between 31,900 and 32,300.

Adjusted free cash flow is now projected between negative $20 million and zero, reflecting about $110 million of cash Capital spending and roughly $35 million of growth investments. Chief Executive Jerome Grant said starts grew 11%, exceeding expectations, while Chief Financial Officer Bruce Schuman said the changes reflect timing and, to a lesser degree, mix, rather than a shift in underlying demand. UTI-Atlanta opened in July 2026 with initial starts about 30% ahead of expectations.

What Investors Should Watch

The next scheduled catalyst is the fiscal fourth-quarter and full-year report; the exact date was not confirmed in the sources reviewed, and the company has historically reported in the weeks after its September 30 year-end. Investors may watch whether fourth-quarter starts land inside the guided range and whether revenue and earnings per share fall within the revised bands. Concorde's performance could draw attention, since its starts declined 1.4% in the quarter while the UTI division grew strongly.

The pace of the multi-year restructuring and any additional charges may affect margins. Balance Sheet items also matter: total Debt was $160.0 million, including $95.0 million drawn on the revolver, against Liquidity of $180.5 million, and negative adjusted free cash flow could potentially increase reliance on borrowing. Campus ramp-ups in Atlanta and San Antonio may offer early evidence on the growth strategy, and the company said San Antonio is tracking well ahead of its launch model.

Growth Spending Versus Thin Margins

UTI's story combines acquired healthcare education capacity, new automotive and trades campuses, and heavier near-term Investment that is compressing margins and cash flow. Confirmed enrollment growth contrasts with a guidance reset that management describes as timing driven. Whether that framing holds will become clearer with year-end results.